These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 36970340

  • 1. Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease.
    Xi H, Liu J, Xu T, Li Z, Mou X, Jin Y, Xia S.
    Front Cardiovasc Med; 2023; 10():1117915. PubMed ID: 36970340
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis.
    Luo Y, Tan N, Zhao J, Li Y.
    Int J Gen Med; 2022; 15():2451-2461. PubMed ID: 35264881
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation.
    Yi M, Tang WH, Xu S, Ke X, Liu Q.
    Front Cardiovasc Med; 2022; 9():837330. PubMed ID: 35669469
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M, Yan X, Wu W.
    BMC Cardiovasc Disord; 2021 Sep 17; 21(1):446. PubMed ID: 34535088
    [Abstract] [Full Text] [Related]

  • 9. Using XGBoost for Predicting In-Stent Restenosis Post-DES Implantation: Role of Lymphocyte-to-Monocyte Ratio and Residual Cholesterol.
    Hou L, Su K, He T, Zhao J, Li Y.
    Int J Gen Med; 2024 Sep 17; 17():3443-3452. PubMed ID: 39139709
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Predictors of in-stent restenosis in coronary heart disease patients complicating with diabetes mellitus within 2 years after drug-eluting stents implantation].
    Chen J, Chen Y, Tian F, Han Y, Jing J, Liu J, Wang J, Zhou S.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jan 17; 42(1):14-8. PubMed ID: 24680263
    [Abstract] [Full Text] [Related]

  • 13. Association of serum apoA-I with in-stent restenosis in coronary heart disease.
    Wang X, Zhang M, Cheng J, Zhou H.
    BMC Cardiovasc Disord; 2022 Aug 04; 22(1):355. PubMed ID: 35927634
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.
    Zhao J, Hou L, Zhu N, Huang R, Su K, Lei Y, Li Y.
    Int J Gen Med; 2023 Aug 04; 16():69-76. PubMed ID: 36636712
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T, Fu Y, Wang Y, Li W, Zhao J, Wang X, Wang H, Zhao Y, Fu X.
    BMC Cardiovasc Disord; 2021 Jan 07; 21(1):24. PubMed ID: 33413149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.